Laboratory Analytical Instruments · SIC 3826

HARVARD BIOSCIENCE INC

HBIO

Watch

Latest revenue

$20.8M

as of 2026-03-31

Latest net income

$-3.4M

as of 2026-03-31

Net margin

-16.5%

as of 2026-03-31

Price · 5Y

-39.8% / yr 53.5 pts / yr vs S&P 500 92.0% total
Compare:

Live market

delayed ≤15 min
$5.59
1.27%
Market cap
$25.2M
Enterprise value
$25.2M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$7.50
52-wk low
$0.28
Beta
Shares out
4.5M

5-year trend

About HBIO

Business description and risk factors will appear here once HBIO's latest filing is fully ingested.

Profitability

Gross margin

57.7%

0.9%

Operating margin

-56.1%

750.7%

Net margin

-65.5%

397.1%

Return on equity

-412.8%

2331.9%

Return on assets

-70.8%

622.9%

Leverage

Debt / equity

4.83×

558.9%

Long-term debt / equity

2.61×

Debt / assets

82.8%

95.9%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$20.8M-4.7%$-3.4M+93.2%-16.5%

Q4 2025

2025-12-31

$23.7M-3.3%$-2.8M-15916.7%-12.0%

Q3 2025

2025-09-30

$20.6M-6.3%$-1.2M+74.4%-6.0%

Q2 2025

2025-06-30

$20.4M-11.5%$-2.3M+22.0%-11.2%

Q1 2025

2025-03-31

$21.8M-11.2%$-50.3M-972.4%-231.2%

Q4 2024

2024-12-31

$24.6M$18.0K0.1%

Q3 2024

2024-09-30

$22.0M-13.4%$-4.8M-287.6%-21.9%

Q2 2024

2024-06-30

$23.1M-19.7%$-2.9M-717.6%-12.7%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Laboratory Analytical Instruments · SIC 3826

No data yet for industry average

Your notes

Keep private notes on HBIO — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$202.4K

Insider selling

$0

Net activity

+$202.4K

Distinct insiders

4

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-03-17

Stephen J Denelsky

Director

Purchase10,000$4.87$48.7K
2026-03-17

William Snider

Director

Purchase8,475$4.85$41.1K
2026-03-16

Mark T Frost

Chief Financial Officer

Purchase5,000$5.00$25.0K
2026-03-16

William Snider

Director

Purchase12,525$4.99$62.5K
2026-03-16

John D Duke

Chief Executive Officer

Purchase5,000$5.01$25.1K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns HBIO

Institutional value

$0

Total shares held

30

Distinct holders

1

-63 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1Financial Connections Group, Inc.30$0-270 (-90.0%)Trimmed

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once HBIO's latest filing finishes processing.